15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $593000 | -$45851 | 0.0% | -8256.3% | -$38M | — | $17M |
| 2024 | $683000 | -$45431 | 0.0% | -7123.1% | -$38M | — | $51M |
| 2023 | $488000 | -$41441 | 0.0% | -9305.7% | -$31M | — | $22M |
| 2022 | $386000 | -$39M | 0.0% | -10337.3% | -$35M | — | $16M |
| 2021 | $359000 | -$28M | 0.0% | -8037.6% | -$23M | — | $12M |
| 2020 | $366000 | -$19M | 0.0% | -5214.8% | -$17M | — | $131M |
| 2019 | — | -$16M | — | — | -$13M | — | $10M |
| 2018 | — | -$16M | — | — | -$13M | — | $11M |
| 2017 | — | -$25M | — | — | — | — | $8M |
| 2016 | — | -$39M | — | — | — | — | $14M |
| 2015 | — | -$27M | — | — | — | — | $67M |
| 2014 | — | -$14M | — | — | — | — | $67M |
| 2014 | — | -$69M | — | — | — | — | $23M |
| 2013 | — | -$12M | — | — | — | — | $26M |
| 2013 | — | -$64M | — | — | — | — | $28M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $41000 | -$12M | 0.0% | -31341.5% | — | — | $9M |
| Dec '25 | $243000 | -$7M | 0.0% | -3221.0% | -$6M | — | $17M |
| Sep '25 | $120000 | -$11M | 0.0% | -9978.3% | -$11M | — | $10M |
| Jun '25 | $121000 | -$14M | 0.0% | -12212.4% | — | — | $11M |
| Mar '25 | $109000 | -$13M | 0.0% | -13194.5% | — | — | $24M |
| Dec '24 | $151000 | -$12M | 0.0% | -8325.8% | -$10M | — | $51M |
| Sep '24 | $165000 | -$12M | 0.0% | -7637.0% | -$10M | — | $13M |
| Jun '24 | $163000 | -$12M | 0.0% | -7696.3% | -$9M | — | $26M |
| Mar '24 | $205000 | -$10M | 0.0% | -5333.2% | -$8M | — | $19M |
| Dec '23 | $156000 | -$9M | 0.0% | -6623.1% | -$7M | — | $22M |
| Sep '23 | $141000 | -$10M | 0.0% | -7673.8% | -$8M | — | $15M |
| Jun '23 | $108000 | -$11M | 0.0% | -11303.7% | -$7M | — | $19M |
| Mar '23 | $83000 | -$11M | 0.0% | -14520.5% | -$9M | — | $15M |
| Dec '22 | $128000 | -$9M | 0.0% | -7337.5% | -$9M | — | $16M |
| Sep '22 | $93000 | -$9M | 0.0% | -9669.9% | -$8M | — | $19M |
| Jun '22 | $91000 | -$10M | 0.0% | -11475.8% | -$7M | — | $21M |
| Mar '22 | $74000 | -$11M | 0.0% | -14964.9% | -$10M | — | $20M |
| Dec '21 | $133000 | -$9M | 0.0% | -7162.4% | -$7M | — | $12M |
| Sep '21 | $86000 | -$7M | 0.0% | -8137.2% | -$6M | — | $13M |
| Jun '21 | $68000 | -$7M | 0.0% | -10130.9% | -$4M | — | $11M |
How the market has priced CRDF against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Cardiff Oncology, Inc.'s revenue has grown 10.1% per year. These are computed facts, not advice.
As of FY2025, Cardiff Oncology, Inc. reported — of total debt against $17M of cash.
In FY2025, gross margin was —, operating margin -8256.3%, and net margin -7.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.